Alivus Life Sciences FY26 Revenue Up 6.9% to ₹2,551.8 Crore; EBITDA Margins at 33.6%
Alivus Life Sciences reported FY26 revenue of ₹2,551.8 crore, up 6.9% YoY. EBITDA grew 19.6% to ₹857.7 crore with margins at 33.6%. PAT increased 16.2% to ₹564.5 crore. The company expects high single-digit revenue growth and sustained margins above 30% for FY27.
The announcement details significant financial performance improvements for the fiscal year and quarter, including robust growth metrics and margin expansion, which are material to investors.
The company reported strong year-on-year growth in revenue, EBITDA, and PAT, along with improved EBITDA margins. Management expressed confidence in future growth and sustained profitability.
Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited) announced its financial results for the quarter and year ended March 31, 2026.
For the full fiscal year 2026, the company reported a Revenue from operations of ₹25,518 million (₹2,551.8 crore), marking a year-on-year growth of 6.9%. For the fourth quarter of FY26, Revenue from operations stood at ₹6,891 million (₹689.1 crore), a 6.1% increase YoY.
EBITDA for FY26 was ₹8,577 million (₹857.7 crore), a 19.6% growth YoY, with EBITDA margins expanding to 33.6%, a significant increase of 360 basis points YoY. In Q4FY26, EBITDA was ₹2,373 million (₹237.3 crore), up 13.8% YoY, and EBITDA margins were 34.4%, up 230 basis points YoY.
Profit After Tax (PAT) for FY26 was ₹5,645 million (₹564.5 crore), a 16.2% increase YoY, with PAT margins at 22.1%, up 180 basis points YoY. For Q4FY26, PAT was ₹1,627 million (₹162.7 crore), a 14.7% growth YoY, and PAT margins were 23.6%, up 180 basis points YoY. The company generated a strong free cash flow of ₹2,590 million (₹259 crore) in FY26, leading to Cash and Cash Equivalents of ₹7,824 million (₹782.4 crore) as of March 31, 2026.
Dr. Yasir Rawjee, MD & CEO, highlighted the strong operating performance in FY26, with revenue growth supported by a 13% increase in non-GPL business and a turnaround in the CDMO business. He expressed confidence in delivering high single-digit revenue growth for FY27 with margins sustained above 30%. Tushar Mistry, CFO, noted the broad-based performance and focus on profitable growth, exceeding the guided EBITDA margin range of 30-32% for FY26.
Additional highlights include cumulative DMF/CEP filings reaching 611 as of March 31, 2026. The company is progressing with capex, including Phase 1 and 1.1 construction for 465 KL capacity at Solapur. Alivus has also acquired land in Taloja (Navi Mumbai) to establish a state-of-the-art R&D center focused on advanced chemistry research, with construction already commenced.
What to do with a filing like this
Alivus Life Sciences Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Alivus Life Sciences Limited. Read the original for the full detail.